249 related articles for article (PubMed ID: 23456516)
1. Ornithine phenylacetate revisited.
Jover-Cobos M; Noiret L; Sharifi Y; Jalan R
Metab Brain Dis; 2013 Jun; 28(2):327-31. PubMed ID: 23456516
[TBL] [Abstract][Full Text] [Related]
2. Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats.
Jover-Cobos M; Noiret L; Lee K; Sharma V; Habtesion A; Romero-Gomez M; Davies N; Jalan R
J Hepatol; 2014 Mar; 60(3):545-53. PubMed ID: 24512823
[TBL] [Abstract][Full Text] [Related]
3. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
Kristiansen RG
Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377
[TBL] [Abstract][Full Text] [Related]
4. Interorgan metabolism of ornithine phenylacetate (OP)--a novel strategy for treatment of hyperammonemia.
Dadsetan S; Sørensen M; Bak LK; Vilstrup H; Ott P; Schousboe A; Jalan R; Keiding S; Waagepetersen HS
Biochem Pharmacol; 2013 Jan; 85(1):115-23. PubMed ID: 23103564
[TBL] [Abstract][Full Text] [Related]
5. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
Jalan R; Wright G; Davies NA; Hodges SJ
Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
[TBL] [Abstract][Full Text] [Related]
6. L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway.
Kristiansen RG; Rose CF; Fuskevåg OM; Mæhre H; Revhaug A; Jalan R; Ytrebø LM
Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G1024-31. PubMed ID: 25258408
[TBL] [Abstract][Full Text] [Related]
7. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.
Kristiansen RG; Rose CF; Ytrebø LM
Metab Brain Dis; 2016 Dec; 31(6):1269-1273. PubMed ID: 27339764
[TBL] [Abstract][Full Text] [Related]
8. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure.
Ytrebø LM; Kristiansen RG; Maehre H; Fuskevåg OM; Kalstad T; Revhaug A; Cobos MJ; Jalan R; Rose CF
Hepatology; 2009 Jul; 50(1):165-74. PubMed ID: 19554542
[TBL] [Abstract][Full Text] [Related]
9. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats.
Davies NA; Wright G; Ytrebø LM; Stadlbauer V; Fuskevåg OM; Zwingmann C; Davies DC; Habtesion A; Hodges SJ; Jalan R
Hepatology; 2009 Jul; 50(1):155-64. PubMed ID: 19437490
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes.
Safadi R; Rahimi RS; Thabut D; Bajaj JS; Ram Bhamidimarri K; Pyrsopoulos N; Potthoff A; Bukofzer S; Wang L; Jamil K; Devarakonda KR
Clin Transl Sci; 2022 Jun; 15(6):1449-1459. PubMed ID: 35238476
[TBL] [Abstract][Full Text] [Related]
11. Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats.
Wright G; Vairappan B; Stadlbauer V; Mookerjee RP; Davies NA; Jalan R
Liver Int; 2012 Mar; 32(3):410-9. PubMed ID: 22151131
[TBL] [Abstract][Full Text] [Related]
12. Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis.
Oria M; Romero-Giménez J; Arranz JA; Riudor E; Raguer N; Córdoba J
J Hepatol; 2012 Jan; 56(1):109-14. PubMed ID: 21835138
[TBL] [Abstract][Full Text] [Related]
13. Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease.
Hadjihambi A; De Chiara F; Hosford PS; Habtetion A; Karagiannis A; Davies N; Gourine AV; Jalan R
Hepatology; 2017 Apr; 65(4):1306-1318. PubMed ID: 28066916
[TBL] [Abstract][Full Text] [Related]
14. Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats.
Balasubramaniyan V; Wright G; Sharma V; Davies NA; Sharifi Y; Habtesion A; Mookerjee RP; Jalan R
Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(1):G145-52. PubMed ID: 21903766
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Rahimi RS; Safadi R; Thabut D; Bhamidimarri KR; Pyrsopoulos N; Potthoff A; Bukofzer S; Bajaj JS
Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2626-2635.e7. PubMed ID: 33069881
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Blanco Vela CI; Poo Ramírez JL
Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
[TBL] [Abstract][Full Text] [Related]
17. Bile-duct ligation renders the brain susceptible to hypotension-induced neuronal degeneration: Implications of ammonia.
Clément MA; Bosoi CR; Oliveira MM; Tremblay M; Bémeur C; Rose CF
J Neurochem; 2021 May; 157(3):561-573. PubMed ID: 33382098
[TBL] [Abstract][Full Text] [Related]
18. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension.
Jalan R; De Chiara F; Balasubramaniyan V; Andreola F; Khetan V; Malago M; Pinzani M; Mookerjee RP; Rombouts K
J Hepatol; 2016 Apr; 64(4):823-33. PubMed ID: 26654994
[TBL] [Abstract][Full Text] [Related]
19. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies.
Wright G; Noiret L; Olde Damink SW; Jalan R
Liver Int; 2011 Feb; 31(2):163-75. PubMed ID: 20673233
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
